Cocrystal Pharma Advances Influenza A Treatment Development

Cocrystal Pharma Inc (COCP) just unveiled an announcement.

Cocrystal Pharma, Inc. has released an update on the progress of its promising compound, CDI-42344, which is currently in clinical development as a treatment and preventive measure for influenza A. The announcement has triggered interest among investors, as it marks a significant step in the company’s efforts to combat this common and challenging illness.

Find detailed analytics on COCP stock on TipRanks’ Stock Analysis page.